Proteomics of Papillary Thyroid Carcinoma

Recruiting

• Conditions: Papillary Thyroid Carcinoma

• Registration Number: NCT02814032
• Lead Sponsor: The Affiliated Hospital of Inner Mongolia Medical University

Brief Summary

Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid carcinoma patients. This study aim to reveal protein expression differences between papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis.

Detailed Description

1. Object: Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer.

2. Clinical information, examination data: Information is obtained from medical record abstraction.

3. Samples: Fresh frozen thyroid tissues from each sample group(normal histology, benign disease, papillary thyroid carcinoma with cervical lymph node metastasis, papillary thyroid carcinoma without cervical lymph node metastasis ).

Study Timeline

• Study Start: 2016-06
• Study First Submitted: 2016-06-23
• Study First Submitted QC: 2016-06-24
• Study First Posted: 2016-06-27
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-18
• Last Update Posted: 2023-07-20
• Primary Completion: 2023-12
• Study Completion: 2024-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Newly diagnosed papillary thyroid carcinoma.
• Undergo thyroidectomy according to the China thyroid association guidelines forthe Management of thyroid nodule and thyroid cancer.

Exclusion Criteria

• Current substance abuse/dependence.
• Daily tobacco and alcohol use.
• Whole neck irradiation or surgery.
• Prior cancer diagnosis or chemotherapy treatment.
• Active autoimmune disorder.
• Uncontrolled allergic condition or asthma.
• Chronic use of oral steroid medication.
• Hormone therapy (estrogen, progestin compounds).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
differences in protein expression	6 months

Trial Locations

Locations (1)

Shan Jin; 🇨🇳 Hohhot, Inner Mongolia, China